Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
28.66
+1.49 (5.48%)
At close: Jan 22, 2026, 4:00 PM EST
28.66
0.00 (0.00%)
After-hours: Jan 22, 2026, 4:00 PM EST
Agios Pharmaceuticals Stock Forecast
Stock Price Forecast
The 8 analysts that cover Agios Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $36.25, which forecasts a 26.48% increase in the stock price over the next year. The lowest target is $25 and the highest is $62.
Price Target: $36.25 (+26.48%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Agios Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 4 | 4 | 4 |
| Buy | 4 | 4 | 4 | 2 | 1 | 1 |
| Hold | 1 | 1 | 1 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 9 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Hold Maintains $20 → $25 | Hold | Maintains | $20 → $25 | -12.77% | Jan 6, 2026 |
| Leerink Partners | Leerink Partners | Buy Maintains $34 → $40 | Buy | Maintains | $34 → $40 | +39.57% | Dec 26, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $48 → $62 | Strong Buy | Maintains | $48 → $62 | +116.33% | Dec 24, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $32 → $38 | Strong Buy | Maintains | $32 → $38 | +32.59% | Dec 24, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $32 → $34 | Strong Buy | Maintains | $32 → $34 | +18.63% | Dec 24, 2025 |
Financial Forecast
Revenue This Year
46.66M
from 36.50M
Increased by 27.83%
Revenue Next Year
109.54M
from 46.66M
Increased by 134.79%
EPS This Year
-7.21
from 11.64
EPS Next Year
-6.55
from -7.21
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 49.9M | 200.6M | ||||
| Avg | 46.7M | 109.5M | ||||
| Low | 42.1M | 70.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 36.7% | 329.9% | ||||
| Avg | 27.8% | 134.8% | ||||
| Low | 15.5% | 51.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -5.86 | -5.06 | ||||
| Avg | -7.21 | -6.55 | ||||
| Low | -7.24 | -7.42 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.